Tenax Therapeutics
Pre-clinicalPulmonary Hypertension (PH) resulting from Heart Failure with preserved Ejection Fraction (HFpEF) is a debilitating, often fatal disease. It’s the most common form of pulmonary hypertension globally. Yet, there are currently no approved treatments for this neglected disease.
Founded
2006
Focus
Small Molecules
About
Pulmonary Hypertension (PH) resulting from Heart Failure with preserved Ejection Fraction (HFpEF) is a debilitating, often fatal disease. It’s the most common form of pulmonary hypertension globally. Yet, there are currently no approved treatments for this neglected disease.
Funding History
3Total raised: $12.2M
Debt$2.5MLincoln Park CapitalJan 15, 2023
PIPE$4.2MUndisclosedMay 15, 2022
PIPE$5.5MUndisclosedMar 15, 2021
Company Info
TypePrivate
Founded2006
LocationMorrisville, United States
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile